Strata Oncology

Recorded changes

Newest observations first. Each interval bounds when the website changed; it is not an exact event date.

1. HeadlineBetween 28 February 2024 and 14 February 2025

   BeforeNext-generation precision oncology

   AfterPrecision Oncology Biomarkers for ADCs and IO

   Observed on the company’s website; business claims are not independently verified.

   earlier archived pagelater archived pageLink to observation
2. HeadlineBetween 15 July 2022 and 28 February 2024

   BeforeComprehensive genomic profiling results for more than 94% of patients

   AfterNext-generation precision oncology

   Observed on the company’s website; business claims are not independently verified.

   earlier archived pagelater archived pageLink to observation
3. HeadlineBetween 29 July 2021 and 15 July 2022

   BeforeDelivering the best possible treatment for each patient

   AfterComprehensive genomic profiling results for more than 94% of patients

   Observed on the company’s website; business claims are not independently verified.

   earlier archived pagelater archived pageLink to observation
4. HiringBetween 1 February 2018 and 17 July 2019

   Added a careers page.

   Observed on the company’s website; business claims are not independently verified.

   earlier archived pagelater archived pageLink to observation
5. New logosBetween 9 February 2017 and 1 February 2018

   Added logo to its homepage: xconomy- -may2017-rgb.png.

   Observed on the company’s website; business claims are not independently verified.

   earlier archived pagelater archived pageLink to observation

How it describes itself

Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.

1. February 2024 – November 2026 · 4 captures · latest observed messagingPrecision Oncology Biomarkers for ADCs and IO

   Learn about the latest developments in the Strata platform, including new features and updates. Explore our comprehensive range of solutions for healthcare professionals and organizations.

   This wording observed 6 November 2026.

   current websiteHistorical capture not publicly available
   Inspect 4 captures in this group

   • 28 February 2024 · Next-generation precision oncology archived page
   • 14 February 2025 · Precision Oncology Biomarkers for ADCs and IO archived page
   • 26 April 2026 · Precision Oncology Biomarkers for ADCs and IO archived page
   • 6 November 2026 · Precision Oncology Biomarkers for ADCs and IO current websiteHistorical capture not publicly available
2. Seen July 2022 · 1 captureComprehensive genomic profiling results for more than 94% of patients

   This wording observed 15 July 2022.

   archived page
3. Seen July 2021 · 1 captureDelivering the best possible treatment for each patient

   This wording observed 29 July 2021.

   archived page

Companies in the same space

Competitors picked by an AI model from the funded startups with the most similar descriptions, judged on those descriptions only. A reading, not a verified market map.

• Predicine predicine.comDirect competitorBoth provide molecular oncology diagnostics including MRD tests and biomarker assays for therapy selection.
• Foresight Diagnostics foresight-dx.comDirect competitorBoth develop and commercialize liquid biopsy MRD assays for cancer monitoring and treatment management.
• Adela adelabio.comPartial overlapBoth offer blood-based oncology MRD diagnostics, though one also focuses on multi-cancer early detection.
• Guardant Health guardanthealth.comPartial overlapBoth deliver precision oncology liquid biopsy tests and analytics for cancer detection and monitoring.
• Biofidelity biofidelity.comPartial overlapBoth provide genomic-based precision medicine diagnostics for cancer patients.
• BillionToOne billiontoone.comPartial overlapBoth offer oncology-focused molecular diagnostic tests and lab services for treatment guidance.
• mDETECT mdetect-inc.comPartial overlapBoth commercialize blood-based assays to monitor cancer progression, relapse and therapy response.
• Aqtual aqtual.comPartial overlapBoth develop cfDNA-based oncology diagnostics to guide therapy selection using blood-based assays.